Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities
Net earnings	$ 2,388	$ 2,078
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	194	192
Amortization of intangible assets	154	209
Stock-based compensation	174	154
Upfront costs related to collaborations	150	16
Other, net	395	(60)
Changes in operating assets and liabilities, net of acquisitions:
Accounts and other receivables	(588)	120
Inventories	(160)	97
Prepaid expenses and other assets	301	(248)
Accounts payable and other liabilities	409	(217)
Cash flows from operating activities	3,417	2,341
Cash flows from investing activities
Acquisitions of Pharmacyclics, Inc., net of cash acquired	(11,488)
Other acquisitions and investments	(794)	(17)
Acquisitions of property and equipment	(260)	(279)
Purchases of investment securities	(851)	(1,160)
Sales and maturities of investment securities	9	300
Cash flows from investing activities	(13,384)	(1,156)
Cash flows from financing activities
Net change in short-term borrowings	(425)	(162)
Proceeds from issuance of long-term debt	16,655
Debt issuance cost	(179)
Dividends paid	(1,604)	(1,314)
Purchases of treasury stock	(5,344)	(353)
Proceeds from the exercise of stock options	101	127
Net transactions with Abbott Laboratories, excluding noncash items		53
Other, net	35	(43)
Cash flows from financing activities	9,239	(1,692)
Effect of exchange rate changes on cash and equivalents	(220)	(2)
Net decrease in cash and equivalents	(948)	(509)
Cash and equivalents, beginning of period	8,348	9,595
Cash and equivalents, end of period	7,400	$ 9,086
Supplemental Schedule of Non-Cash Investing and Financing Activities
Issuance of common stock associated with the acquisition of Pharmacyclics, Inc.	$ 8,405